Supreme Court Temporarily Blocks Nationwide Ban on Telemedicine Abortion Access
Similar Articles
Supreme Court Extends Telemedicine Access to Abortion Pill Mifepristone Through Thursday
Supreme Court Maintains Telehealth Access to Abortion Pill Mifepristone
Supreme Court Temporarily Restores Mail-Order Access to Abortion Pill Mifepristone
Appeals Court Blocks Mailing of Abortion Pill Mifepristone, Reinstates In-Person Requirement
Federal Appeals Court Reinstates In-Person Requirement for Mifepristone
The U.S. Supreme Court has paused a lower court ruling that would have reinstated an in-person requirement for the abortion medication mifepristone. The one-week hold means telemedicine prescriptions and mail delivery can continue at least through May 11. The case, brought by Louisiana, challenges the FDA's policy allowing remote access to the drug.
Facts First
- The Supreme Court placed a lower court ruling on hold for one week on Monday, temporarily blocking a nationwide ban on telemedicine access to mifepristone.
- A panel of judges on the 5th Circuit Court of Appeals had ruled in favor of Louisiana on May 1, reinstating an in-person requirement for the medication.
- Telemedicine abortion currently accounts for one quarter of all abortions in the United States, according to estimates.
- Louisiana is the first state to schedule mifepristone as a controlled substance and to criminally indict an out-of-state physician providing telemedicine abortion.
- The FDA made its telemedicine policy for mifepristone official in 2023, after first allowing it during the COVID-19 pandemic.
What Happened
The Supreme Court placed a lower court ruling on hold for one week on Monday. This action temporarily blocks a ruling from the 5th Circuit Court of Appeals that had reinstated an in-person requirement for the abortion medication mifepristone nationwide. The hold means mifepristone can be prescribed through telemedicine and sent through the mail through at least May 11. The 5th Circuit ruling came after Louisiana appealed a district court judge's decision to put the state's lawsuit against the FDA on hold in April. Louisiana sued the FDA last fall, arguing that telemedicine access undermines the state's strict abortion ban.
Why this Matters to You
If you or someone you know relies on medication abortion, this legal back-and-forth directly affects access to care. The immediate impact is that, for now, you can still obtain mifepristone via a telehealth appointment and receive it by mail. This could change after May 11, depending on the Supreme Court's next action. Telemedicine abortion currently accounts for one quarter of abortions across the United States, indicating a significant number of people could be affected by a permanent ruling. The case also highlights a broader legal conflict between state and federal authority over reproductive healthcare.
What's Next
The Supreme Court's one-week hold is temporary. The justices may decide to extend the hold, hear arguments on the case, or allow the 5th Circuit's ruling to take effect after May 11. A related mifepristone case remains active in Missouri, and the Department of Justice has argued for the current case to be put on hold until the end of the year. Nearly two dozen Democratic-led states and a group of former FDA leaders have submitted amicus briefs in the case, which suggests continued legal and political debate is likely.